These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 2203218)

  • 1. Twelve-hour IOP control obtained by a single dose of timolol/pilocarpine combination eye drops.
    Løfors KT; Høvding G; Viksmoen L; Aasved H; Bergaust B; Bulie T
    Acta Ophthalmol (Copenh); 1990 Jun; 68(3):323-6. PubMed ID: 2203218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Timolol/pilocarpine combination eye drops in open angle glaucoma and in ocular hypertension. A controlled randomized study.
    Høvding G; Aasved H
    Acta Ophthalmol (Copenh); 1987 Oct; 65(5):594-601. PubMed ID: 3321877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined timolol and pilocarpine vs pilocarpine alone and timolol alone in the treatment of glaucoma.
    Zadok D; Geyer O; Zadok J; Lazar M; Krakowski D; Nemet P
    Am J Ophthalmol; 1994 Jun; 117(6):728-31. PubMed ID: 8198156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group.
    Bucci MG
    J Glaucoma; 1999 Feb; 8(1):24-30. PubMed ID: 10084271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of changing from concomitant timolol pilocarpine to bimatoprost monotherapy on ocular blood flow and IOP in primary chronic angle closure glaucoma.
    Agarwal HC; Gupta V; Sihota R
    J Ocul Pharmacol Ther; 2003 Apr; 19(2):105-12. PubMed ID: 12804055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with beta adrenergic antagonists. French Latanoprost Study Group, and the Swedish Latanoprost Study Group.
    Nordmann JP; Söderström M; Rouland JF; Malecaze F
    Br J Ophthalmol; 2000 Feb; 84(2):181-5. PubMed ID: 10655195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of latanoprost versus pilocarpine/timolol maleate fixed combination in patients with primary open-angle glaucoma or ocular hypertension.
    Kałuzny J; Sobecki R; Czechowicz-Janicka K; Kecik D; Kałuzny BJ; Stewart JA; Stewart WC
    Acta Ophthalmol; 2008 Dec; 86(8):860-5. PubMed ID: 18721251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. The Dorzolamide Additivity Study Group.
    Strahlman ER; Vogel R; Tipping R; Clineschmidt CM
    Ophthalmology; 1996 Aug; 103(8):1283-93. PubMed ID: 8764800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two fixed beta-blocker-pilocarpine combinations. The Carteolol-Pilocarpine Study Group.
    Bron AM; Garcher CP; Sirbat D; Allaire CM; Lablache-Combier MJ; Trinquand CJ
    Eur J Ophthalmol; 1997; 7(4):351-6. PubMed ID: 9457458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-year safety study of dorzolamide as monotherapy and with timolol and pilocarpine. Dorzolamide Safety Study Group.
    Adamsons IA; Polis A; Ostrov CS; Boyle JE
    J Glaucoma; 1998 Dec; 7(6):395-401. PubMed ID: 9871861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of bimatoprost/timolol fixed combination in Chinese patients with open-angle glaucoma or ocular hypertension.
    Ling Z; Zhang M; Hu Y; Yin Z; Xing Y; Fang A; Ye J; Chen X; Liu D; Wang Y; Sun W; Dong Y; Sun X
    Chin Med J (Engl); 2014; 127(5):905-10. PubMed ID: 24571886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term effect of apraclonidine on intraocular pressure in glaucoma patients receiving timolol and pilocarpine.
    Yüksel N; Elibol O; Caglar Y; Alçelik T
    Ophthalmologica; 1997; 211(6):354-7. PubMed ID: 9380353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dorzolamide/timolol combination versus timolol plus pilocarpine: patient preference and impact on daily life. United States Patient Preference Study Group. International Patient Preference Study Group.
    Sverrisson T; Gross R; Pearson J; Rusk C; Adamsons I
    J Glaucoma; 1999 Oct; 8(5):315-24. PubMed ID: 10529932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.
    Easthope SE; Perry CM
    Drugs Aging; 2002; 19(3):231-48. PubMed ID: 12027782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect on the 24-hour diurnal curve of intraocular pressure of a fixed ratio combination of timolol 0.5% and pilocarpine 2% in patients with COAG not controlled on timolol 0.5%.
    Maclure GM; Vogel R; Sturm A; Binkowitz B
    Br J Ophthalmol; 1989 Oct; 73(10):827-31. PubMed ID: 2818993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of elevated intraocular pressure with concurrent levobunolol and pilocarpine.
    David R; Ober M; Masi R; Elman J; Novack GD; Sears ML; Batoosingh AL
    Can J Ophthalmol; 1987 Jun; 22(4):208-11. PubMed ID: 2886200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Latanoprost : an update of its use in glaucoma and ocular hypertension.
    Perry CM; McGavin JK; Culy CR; Ibbotson T
    Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.
    García-López A; Paczka JA; Jiménez-Román J; Hartleben C
    BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative evaluation of pilocarpine 1% and clonidine 0.125% versus timolol 0.5%.
    Sihota R; Agarwal HC; Rajashekar YL
    Indian J Ophthalmol; 1996 Jun; 44(2):87-9. PubMed ID: 8916595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ocular hypotensive effects and safety over 3 months of switching from an unfixed combination to latanoprost 0.005%/timolol maleate 0.5% fixed combination.
    Inoue K; Okayama R; Higa R; Sawada H; Wakakura M; Tomita G
    J Ocul Pharmacol Ther; 2011 Dec; 27(6):581-7. PubMed ID: 22011049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.